SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

Supernus Pharmaceuticals (SUPN) will acquire Sage Therapeutics (SAGE) for $8.50 per share in cash plus a contingent value right of up to $3.50 per share, totaling $795 million; SAGE shares rose 35.4% on the news. The deal provides SUPN with rights to Zurzuvae, the first oral postpartum depression drug, launched in late 2023 and marketed in partnership with Biogen (BIIB), with SUPN set to recognize 50% of Biogen's U.S. net sales. SUPN expects the acquisition to be accretive in 2026 and diversify its neuroscience portfolio, outbidding a previous offer from Biogen.

Analysis

Supernus Pharmaceuticals (SUPN) has agreed to acquire Sage Therapeutics (SAGE) in a deal valued at approximately $795 million, comprising $8.50 per share in cash and a non-tradable contingent value right (CVR) of up to $3.50 per share. This offer represents a premium of nearly 32% to SAGE's closing price on June 16, and resulted in SAGE shares surging 35.4% on the announcement day. Year-to-date, SAGE shares have appreciated 23.4%, contrasting with an industry decline of 0.8%. The transaction, expected to close in Q3 2025, grants SUPN rights to Zurzuvae, the first FDA-approved oral treatment for postpartum depression (PPD), which SAGE launched in December 2023 and co-markets with Biogen (BIIB). SAGE's collaboration revenues from Zurzuvae were $13.8 million in Q1 2025 and $36.1 million in 2024, with initial uptake reportedly exceeding expectations. Post-acquisition, SUPN will recognize 50% of Biogen's U.S. net sales of Zurzuvae. Supernus anticipates this acquisition will be significantly accretive in 2026, diversifying its revenue base and strengthening its neuroscience portfolio. Notably, SUPN's bid surpasses a previous $7.22 per share offer for SAGE made by Biogen in January 2025, which SAGE rejected as undervaluing the company; Biogen currently holds a 10.2% stake in SAGE.

Key Decisions for Investors

• SAGE investors should assess the total potential value of $12.00 per share, considering the guaranteed $8.50 cash versus the milestone-dependent $3.50 CVR, and the extended closing timeline to Q3 2025.
• SUPN investors should view this as a strategic move to enhance its neuroscience franchise with a novel drug, Zurzuvae, but must also factor in integration execution, the financial burden of the CVR if milestones are met, and the timeline to accretion in 2026.
• Investors should monitor Zurzuvae's sales performance closely as it is a key value driver for the acquisition's success and the CVR payout.
• Consider that Biogen, having been outbid after an earlier attempt to acquire SAGE at a lower price, may see altered dynamics in its partnership for Zurzuvae and its strategic positioning in the CNS market.